Gorilla Fund III makes its 20th investment: Menken Trials joins the portfolio ✨
Menken Trials is redefining compliance and quality in clinical trials by replacing time-consuming manual work with advanced AI. The platform automates critical compliance checks that are traditionally handled by local and central teams, ensuring that every aspect of a clinical trial meets rigorous regulatory standards in real time. By eliminating repetitive tasks and reducing human error, Menken Trials allows research teams to focus on advancing new treatments with confidence, knowing their trials are always audit-ready. This shift not only accelerates the clinical trial process but also sets a new standard for quality and efficiency in research.
As Anna-Liisa Parts, COO and co-founder of Menken Trials, puts it:
“At Menken Trials, we’re on a mission to transform clinical trial quality and compliance through intelligent automation. Together with Gorilla, we believe we can reach new heights in efficiency and precision, setting a new industry standard.“
From our perspective at Gorilla Capital, Menken Trials is an exceptional company in its field. Ami Rubinstein, Partner at Gorilla, highlights:
“Menken Trials has built a unique solution that simplifies the clinical trial process, empowering research teams to maintain compliance effortlessly. Their innovative approach and commitment to quality make them a standout in the clinical trial industry.“
We’re excited to support Menken Trials in their journey to redefine clinical research.
https://lnkd.in/dMsE3YX9
